Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…
TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
Antibody-drug conjugates show promise for lung cancer after TKI failure
This systematic review and meta-analysis of 1092 patients found that antibody-drug conjugates (ADCs) provide significant clinical benefits f…
New research highlights how specific antibody-drug conjugates may offer better outcomes for patients with certain types of lung cancer.
Sacituzumab Tirumotecan Combined With Pembrolizumab Improves Outcomes in PD-L1 Positive NSCLC
Trial shows combination therapy improves survival in lung cancer
A Phase 3 trial shows that adding sacituzumab tirumotecan to pembrolizumab significantly extends progression-free survival in advanced NSCLC…
A new drug combination significantly extends the time patients with advanced lung cancer live without their disease progressing.